NAION typically causes sudden, painless vision loss in one eye and may also produce blind spots, reduced peripheral vision, diminished color perception, or permanent visual impairment
The question of whether these agents can be safely used together requires careful consideration of pharmacological properties, clinical evidence, and FDA guidance regarding thyroid-related safety concerns specific to GLP-1 receptor agonists
Prostate cancer: Causes, symptoms, and diagnosis
Sleep quality at higher doses is often better than at lower doses because more significant weight loss has occurred, potentially improving conditions like overall treatment response and sleep apnea
Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them particularly once market competition makes these drugs more accessible